Strides CEO: US COMPETES Act Creates Quality Differentiator
Examining Upcoming HIV Therapies
Executive Summary
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
You may also be interested in...
Will Pfizer's Paxlovid Go The Lagevrio Way In India?
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?
Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US has sparked interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?
Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?
Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US spark interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?